Synmosa Biopharma (4114) - Net Assets
Based on the latest financial reports, Synmosa Biopharma (4114) has net assets worth NT$10.10 Billion TWD (≈ $318.18 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$13.99 Billion ≈ $440.61 Million USD) and total liabilities (NT$3.89 Billion ≈ $122.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4114 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$10.10 Billion |
| % of Total Assets | 72.21% |
| Annual Growth Rate | 12.85% |
| 5-Year Change | 65.69% |
| 10-Year Change | 132.02% |
| Growth Volatility | 13.98 |
Synmosa Biopharma - Net Assets Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's net assets have evolved over time, based on quarterly financial data. Also explore Synmosa Biopharma balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Synmosa Biopharma (2015–2025)
The table below shows the annual net assets of Synmosa Biopharma from 2015 to 2025. For live valuation and market cap data, see Synmosa Biopharma market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$10.10 Billion ≈ $318.18 Million |
+20.25% |
| 2024-12-31 | NT$8.40 Billion ≈ $264.61 Million |
+3.68% |
| 2023-12-31 | NT$8.10 Billion ≈ $255.22 Million |
+21.84% |
| 2022-12-31 | NT$6.65 Billion ≈ $209.47 Million |
+9.08% |
| 2021-12-31 | NT$6.10 Billion ≈ $192.04 Million |
+2.36% |
| 2020-12-31 | NT$5.95 Billion ≈ $187.60 Million |
+23.72% |
| 2019-12-31 | NT$4.81 Billion ≈ $151.63 Million |
+7.31% |
| 2018-12-31 | NT$4.49 Billion ≈ $141.31 Million |
+13.11% |
| 2017-12-31 | NT$3.97 Billion ≈ $124.93 Million |
-8.90% |
| 2016-12-31 | NT$4.35 Billion ≈ $137.14 Million |
+44.41% |
| 2015-12-31 | NT$3.01 Billion ≈ $94.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Synmosa Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1260.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$899.07 Million | 10.26% |
| Other Components | NT$7.86 Billion | 89.74% |
| Total Equity | NT$8.76 Billion | 100.00% |
Synmosa Biopharma Competitors by Market Cap
The table below lists competitors of Synmosa Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korla Pear
SHG:600506
|
$488.36 Million |
|
PSK HOLDINGS Inc
KQ:031980
|
$488.38 Million |
|
Euroseas Ltd
NASDAQ:ESEA
|
$488.48 Million |
|
Titan International Inc
NYSE:TWI
|
$488.50 Million |
|
Hyundai Motor Securities Co. Ltd.
KO:001500
|
$488.17 Million |
|
Menif Financial Services Ltd
TA:MNIF
|
$488.09 Million |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
$487.87 Million |
|
Just Dial Limited
NSE:JUSTDIAL
|
$487.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Synmosa Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,210,162,000 to 8,763,824,000, a change of 1,553,662,000 (21.5%).
- Net income of 821,849,000 contributed positively to equity growth.
- Dividend payments of 272,614,000 reduced retained earnings.
- New share issuances of 1,108,642,000 increased equity.
- Other factors decreased equity by 104,215,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$821.85 Million | +9.38% |
| Dividends Paid | NT$272.61 Million | -3.11% |
| Share Issuances | NT$1.11 Billion | +12.65% |
| Other Changes | NT$-104.22 Million | -1.19% |
| Total Change | NT$- | 21.55% |
Book Value vs Market Value Analysis
This analysis compares Synmosa Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.60x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$11.86 | NT$30.80 | x |
| 2018-12-31 | NT$14.10 | NT$30.80 | x |
| 2019-12-31 | NT$14.06 | NT$30.80 | x |
| 2020-12-31 | NT$16.84 | NT$30.80 | x |
| 2021-12-31 | NT$15.83 | NT$30.80 | x |
| 2022-12-31 | NT$16.24 | NT$30.80 | x |
| 2023-12-31 | NT$15.83 | NT$30.80 | x |
| 2024-12-31 | NT$15.40 | NT$30.80 | x |
| 2025-12-31 | NT$17.36 | NT$30.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Synmosa Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.38%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.28%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.60x
- Recent ROE (9.38%) is above the historical average (7.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 1.38% | 1.78% | 0.39x | 2.01x | NT$-196.66 Million |
| 2016 | 5.48% | 8.93% | 0.27x | 2.23x | NT$-137.47 Million |
| 2017 | 0.16% | 0.25% | 0.25x | 2.62x | NT$-281.17 Million |
| 2018 | 13.40% | 18.23% | 0.31x | 2.35x | NT$109.23 Million |
| 2019 | 1.35% | 1.76% | 0.31x | 2.51x | NT$-301.28 Million |
| 2020 | 14.18% | 21.00% | 0.29x | 2.31x | NT$188.10 Million |
| 2021 | 6.46% | 9.39% | 0.31x | 2.19x | NT$-166.69 Million |
| 2022 | 15.04% | 18.22% | 0.39x | 2.11x | NT$267.91 Million |
| 2023 | 8.87% | 11.57% | 0.44x | 1.75x | NT$-76.12 Million |
| 2024 | 9.50% | 12.34% | 0.45x | 1.71x | NT$-36.33 Million |
| 2025 | 9.38% | 13.28% | 0.44x | 1.60x | NT$-54.53 Million |
Industry Comparison
This section compares Synmosa Biopharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,692,263,800
- Average return on equity (ROE) among peers: 5.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Synmosa Biopharma (4114) | NT$10.10 Billion | 1.38% | 0.38x | $488.27 Million |
| Grape King Bio Ltd (1707) | $1.77 Billion | 10.20% | 0.42x | $525.05 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.98 Billion | 9.81% | 0.25x | $343.42 Million |
| Maywufa Co Ltd (1731) | $1.65 Billion | 2.55% | 0.49x | $90.87 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.54 Billion | 4.20% | 0.19x | $509.46 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $7.70 Billion | 0.10% | 1.03x | $1.86 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $788.18 Million | -2.86% | 0.45x | $49.11 Million |
| LIWANLI Innovation Co Ltd (3054) | $661.02 Million | 0.00% | 0.12x | $170.50 Million |
| YungShin Global Holding Corp (3705) | $5.06 Billion | 9.31% | 0.15x | $461.56 Million |
| TTY Biopharm Co Ltd (4105) | $7.51 Billion | 19.30% | 0.45x | $581.27 Million |
| Phytohealth Corp (4108) | $2.27 Billion | -2.08% | 0.04x | $76.03 Million |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more